The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
Award for Outstanding Journal Article | Cancer Prevention Research | American Association for Cancer Research #aacrcontent {font-size: 16px;} .right { float: right; margin: 0 16px…
Kidney and Renal Pelvis Cancer statistics
FDA Oncology Center of Excellence has formed the OCE Equity Program. To access this subscriber-only content please log in or subscribe.If your institution has a…
While Dato-DXd numerically improved overall survival for patients with non-small cell lung cancer, the data did not show statistical significance. However, a clinically meaningful benefit…
Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the presentation and pathology of Rosai-Dorfman disease.
This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during…
Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.
Blood and bone marrow transplant innovation is increasing access to life-saving procedures for many older cancer patients.
Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.